trending Market Intelligence /marketintelligence/en/news-insights/trending/lrxfzoow4bdf0c-onik7zq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Aradigm to delist from Nasdaq

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Aradigm to delist from Nasdaq

Aradigm Corp.'s common stock will be suspended from Nasdaq trading on Sept. 14.

The delisting comes after Aradigm failed to regain compliance with the exchange's $35 million minimum market value of listed securities. Aradigm received the noncompliance notice in March, and had until Sept. 4 to regain compliance.

Aradigm may request a hearing to appeal the delisting, and stay the suspension. The company said it is evaluating available options to regain compliance.

Hayward, Calif.-based Aradigm develops drugs for the prevention and treatment of severe respiratory diseases.